Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.

Pawlyn, C., Royle, K.-L. orcid.org/0000-0003-0225-1199, Senior, E. et al. (20 more authors) (2025) Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT. In: Blood. 67th ASH Annual Meeting, 06-09 Dec 2025, Orlando, Florida. Vol. 146 (Supplement 1). American Society of Hematology, pp. 369-370. ISSN: 0006-4971. EISSN: 1528-0020.

Metadata

Item Type: Conference abstract
Authors/Creators:
Dates:
  • Published (online): 3 November 2025
  • Published: 3 November 2025
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Funding Information:
Funder
Grant number
Cancer Research UK Supplier No: 138573
A25447
Cancer Research UK Supplier No: 138573
CTUQQR-Dec22/100002
Takeda UK Ltd. Building 3, Glory Park
Not Known
Millennium Pharmaceuticals Inc.
X160111
Date Deposited: 14 May 2026 08:52
Last Modified: 14 May 2026 08:52
Published Version: https://ashpublications.org/blood/article/146/Supp...
Status: Published
Publisher: American Society of Hematology
Identification Number: 10.1182/blood-2025-369
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)